Abhya Gupta
- Efficacy of BIBF 1120 in patients with IPF is dose-dependent: Results from the TOMORROW trialBy Ulrich Costabel, Luca Richeldi, Moises Selman, Dong Soon Kim, Kevin K. Brown, Kevin R. Flaherty, Paul W. Noble, Ganesh Raghu, Michèle Brun, Abhya Gupta, Matthias Klueglich, Nolwenn Juhel and Roland M. du BoisUlrich Costabel1Ruhrlandklinik and Medical Faculty, University of Duisburg-Essen, Essen, GermanyLuca Richeldi2Center for Rare Lung Disease, University of Modena and Reggio Emilia, Modena, ItalyMoises Selman3Instituto Nacional de Enfermedades Respiratorias, “Ismael Cosio Villegas”, México, MexicoDong Soon Kim4Division of Pulmonary and Critical Care Medicine, Asan Medical Center, Seoul, KoreaKevin K. Brown5Division of Pulmonary Sciences and Critical Care Medicine, Department of Medicine, National Jewish Health, Denver, United StatesKevin R. Flaherty6Department of Internal Medicine, Pulmonary and Critical Care Division, University of Michigan, Ann Arbor, United StatesPaul W. Noble7Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine, Duke University Medical Center, Durham, United StatesGanesh Raghu8Division of Pulmonary and Critical Care Medicine, University of Washington, Seattle, United StatesMichèle Brun9Boehringer Ingelheim France S.A.S., Boehringer Ingelheim, Reims, FranceAbhya Gupta10Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim, Biberach, GermanyMatthias Klueglich10Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim, Biberach, GermanyNolwenn Juhel9Boehringer Ingelheim France S.A.S., Boehringer Ingelheim, Reims, FranceRoland M. du Bois11National Heart & Lung Institute, Imperial College, London, United Kingdom
- Effect of baseline FVC on preservation of lung function with BIBF 1120: Results from the TOMORROW trialBy Luca Richeldi, Ulrich Costabel, Moises Selman, Dong Soon Kim, Kevin R. Flaherty, Paul W. Noble, Ganesh Raghu, Arata Azuma, Michèle Brun, Abhya Gupta, Matthias Klueglich, Nolwenn Juhel and Roland M. du BoisLuca Richeldi1Center for Rare Luna Disease, University of Modena and Reggio Emilia, Modena, ItalyUlrich Costabel2Ruhrlandklinik and Medical Faculty, University of Duisburg-Essen, Essen, GermanyMoises Selman3Instituto Nacional de Enfermedades Respiratorias, “Ismael Cosio Villegas”, Mèxico, MexicoDong Soon Kim4Division of Pulmonary and Critical Care Medicine, Asan Medical Center, University of Ulsan, Seoul, KoreaKevin R. Flaherty5Department of Internal Medicine, Pulmonary and Critical Care Division, University of Michigan, Ann Arbor, United StatesPaul W. Noble6Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine, Duke University Medical Center, Durham, United StatesGanesh Raghu7Division of Pulmonary and Critical Care Medicine, University of Washington, Seattle, United StatesArata Azuma8Division of Respiratory Medicine, Infection and Oncology, Nippon Medical School, Tokyo, JapanMichèle Brun9Boehringer Ingelheim France S.A.S., Boehringer Ingelheim, Reims, FranceAbhya Gupta10Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim, Biberach, GermanyMatthias Klueglich10Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim, Biberach, GermanyNolwenn Juhel9Boehringer Ingelheim France S.A.S., Boehringer Ingelheim, Reims, FranceRoland M. du Bois11National Heart & Lung Institute, Imperial College, London, United Kingdom
- Efficacy and safety of BI 671800, an oral CRTH2 antagonist in controller naïve patients with poorly-controlled asthmaBy Rand Sutherland, Kay Tetzlaff, Chad Nivens, Miguel Tsukayama, Alfredo Guerreros, Raymond Manuel, Eric Bateman, Jon Blatchford, Andrew Fowler and Abhya GuptaRand Sutherland1Pulmonary and Critical Care Medicine, National Jewish Health, Denver, United StatesKay Tetzlaff2Clinical Development & Medical Affairs/Therapeutic Area Respiratory Diseases, Boehringer Ingelheim Pharmaceuticals, Inc, Ridgefield,, United StatesChad Nivens3Clinical Development & Medical Affairs/Therapeutic Area Respiratory Diseases, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riss, GermanyMiguel Tsukayama4Pulmonary Medicine, Clinica Ricardo Palma, San Isidro, Lima 27, PeruAlfredo Guerreros5Jefe de la Unidad de Investigacio y Docencia, Clinica International, Lima, PeruRaymond Manuel6Clinical Operations, Boehringer Ingelheim Pharmaceuticals, Inc, Ridgefield, United StatesEric Bateman7Department of Medicine, University of Cape Town, South AfricaJon Blatchford8Clinical Development & Medical Affairs/Therapeutic Area Respiratory Diseases, Boehringer Ingelheim Ltd, Bracknell, United KingdomAndrew Fowler8Clinical Development & Medical Affairs/Therapeutic Area Respiratory Diseases, Boehringer Ingelheim Ltd, Bracknell, United KingdomAbhya Gupta3Clinical Development & Medical Affairs/Therapeutic Area Respiratory Diseases, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riss, Germany
- Efficacy and safety of BI 671800, an oral CRTH2 antagonist, as add on therapy in poorly controlled asthma patients prescribed an inhaled corticosteroidBy Ian Hall, Maria Sarno, Bernd Disse, Sibel Atis, Ekkehard Beck, Eric Bateman, Helen Finnigan, Christoph Hallmann, Abhya Gupta and Andrew FowlerIan Hall1Department of Respiratory Disease, University of Nottingham, United KingdomMaria Sarno2Clinical Development & Medical Affairs/Therapeutic Area Respiratory Diseases, Boehringer Ingelheim Ltd, Bracknell, United KingdomBernd Disse3Clinical Development & Medical Affairs/Therapeutic Area Respiratory Diseases, Boehringer Ingelheim GmBH, Ingelheim, GermanySibel Atis4Department of Chest Disease, Mersin University School of Medicine, Mersin, TurkeyEkkehard Beck5Department of Clinical Research, IFG Institut fuer Gesundheitsfoerderung, Ruedersdorf, GermanyEric Bateman6Department of Medicine, University of Cape Town, South AfricaHelen Finnigan2Clinical Development & Medical Affairs/Therapeutic Area Respiratory Diseases, Boehringer Ingelheim Ltd, Bracknell, United KingdomChristoph Hallmann3Clinical Development & Medical Affairs/Therapeutic Area Respiratory Diseases, Boehringer Ingelheim GmBH, Ingelheim, GermanyAbhya Gupta7Clinical Development & Medical Affairs/Therapeutic Area Respiratory Diseases, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riss, GermanyAndrew Fowler2Clinical Development & Medical Affairs/Therapeutic Area Respiratory Diseases, Boehringer Ingelheim Ltd, Bracknell, United Kingdom
- Efficacy and safety of BI 671800, an oral CRTH2 antagonist, as add on therapy in poorly controlled asthma patients prescribed an inhaled corticosteroidBy David Miller, Craig LaForce, Albert Finn, Eric Bateman, Kristin Drda, Jon Blatchford, Wanda Broderick, Andrew Fowler, Abhya Gupta and Chester WoodDavid Miller1Clinical Research, CRN/Allergy & Respiratory, North Dartmouth, United StatesCraig LaForce2Clinical Research, Pediatrics, Allergy and Immunology, Raleigh, United StatesAlbert Finn3Clinical Research, National Allergy Asthma & Urticaria Centers, North Charleston, United StatesEric Bateman4Department of Medicine, University of Cape Town, South AfricaKristin Drda5Clinical Development & Medical Affairs/Therapeutic Area Respiratory Diseases, Boehringer Ingelheim Pharmaceuticals, Inc, Ridgefield, United StatesJon Blatchford6Clinical Development & Medical Affairs/Therapeutic Area Respiratory Diseases, Boehringer Ingelheim Ltd, Bracknell, United KingdomWanda Broderick5Clinical Development & Medical Affairs/Therapeutic Area Respiratory Diseases, Boehringer Ingelheim Pharmaceuticals, Inc, Ridgefield, United StatesAndrew Fowler6Clinical Development & Medical Affairs/Therapeutic Area Respiratory Diseases, Boehringer Ingelheim Ltd, Bracknell, United KingdomAbhya Gupta7Clinical Development & Medical Affairs/Therapeutic Area Respiratory Diseases, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riss, GermanyChester Wood5Clinical Development & Medical Affairs/Therapeutic Area Respiratory Diseases, Boehringer Ingelheim Pharmaceuticals, Inc, Ridgefield, United States
Buying books on this site
Purchases made on this website are of electronic books only.
About the ERS books
The ERS Monograph is the quarterly book series from the European Respiratory Society. Each Monograph covers a specific area of respiratory medicine, providing in-depth reviews that give clinicians at all levels a concise, comprehensive guide to symptoms, diagnosis and treatment.
The ERS Handbooks are compact guides to broad areas of the respiratory field. Launched in 2010, the series now covers adult, paediatric and sleep respiratory medicine, includes a companion volume of self-assessment questions and features the ERS Practical Handbooks.